The Use of Angiotensin Receptor Blockers and the Risk of Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,165,781
- 主要终点
- Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan, relative to beta-blockers and diuretics
研究概览
简要总结
The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD)
排除标准
- •History of cancer at any time prior to cohort entry
研究组 & 干预措施
Patients prescribed antihypertensives
干预措施: ARB (Drug)
Patients prescribed antihypertensives
干预措施: ACEI (Drug)
Patients prescribed antihypertensives
干预措施: Beta-blockers (Drug)
Patients prescribed antihypertensives
干预措施: Diuretics (Drug)
Patients prescribed antihypertensives
干预措施: Telmisartan (Drug)
结局指标
主要结局
Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan, relative to beta-blockers and diuretics
时间窗: 16 years
Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of telmisartan relative to other ARBs
时间窗: 16 years
Number of patients with occurrences of lung, colorectal, breast and prostate cancers related to use of ARBs
时间窗: 16 years
Determination of dose-response in terms of ARB duration of use and cumulative dose and the risk of lung, colorectal, breast and prostate cancers combined
时间窗: 16 years
Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of ARBs, relative to beta-blockers and diuretics
时间窗: 16 years
次要结局
- Number of patients with occurrences of lung cancer related to use of ARBs with ACEI(16 years)
- Number of patients with occurrences of breast cancer related to use of ARBs with ACEI(16 years)
- Number of patients with occurrences of lung cancer related to use of ARBs alone(16 years)
- Number of patients with occurrences of breast cancer related to use of ARBs alone(16 years)
- Ratio of occurrence of colorectal cancer related to use of telmisartan relative to other ARBs(16 years)
- Number of patients with occurrences of prostate cancer related to use of ARBs with ACEI(16 years)
- Ratio of occurrence of lung cancer related to use of telmisartan relative to other ARBs(16 years)
- Ratio of occurrence of prostate cancer related to use of telmisartan relative to other ARBs(16 years)
- Number of patients with occurrences of prostate cancer related to use of ARBs alone(16 years)
- Number of patients with occurrences of colorectal cancer related to use of ARBs alone(16 years)
- Number of patients with occurrences of colorectal cancer related to use of ARBs with ACEI(16 years)
- Ratio of occurrence of breast cancer related to use of telmisartan relative to other ARBs(16 years)